{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:42:45Z","timestamp":1791492165373,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ekir.2022.01.1073","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:05:53Z","timestamp":1644278753000},"page":"993-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers"],"prefix":"10.1016","volume":"7","author":[{"given":"Mohit","family":"Mathur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-7229","authenticated-orcid":false,"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Engler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Yarbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Oldach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2022.01.1073_bib1","article-title":"Pathogenic role of a proliferation-inducing ligand (APRIL) in murine IgA nephropathy","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2022.01.1073_bib2","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1681\/ASN.2015060677","article-title":"The role of TNF superfamily member 13 in the progression of IgA nephropathy","volume":"27","author":"Han","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2022.01.1073_bib4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib5","doi-asserted-by":"crossref","first-page":"103925","DOI":"10.1016\/j.cellimm.2019.103925","article-title":"A\u00a0proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy","volume":"341","author":"Takahara","year":"2019","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.kint.2019.08.022","article-title":"TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy","volume":"97","author":"Makita","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1073_bib7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.ekir.2022.01.1073_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.2966","article-title":"Association of TNFSF13 polymorphisms with IgA nephropathy in a Chinese Han population","volume":"19","author":"Zhong","year":"2017","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.ekir.2022.01.1073_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib10","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.0307348101","article-title":"Impaired IgA class switching in APRIL-deficient mice","volume":"101","author":"Castigli","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2022.01.1073_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ekir.2022.01.1073_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells [published correction appears in J Clin Invest. 2004;113:1069]","volume":"112","author":"Avery","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.01.1073_bib13","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI0215034","article-title":"APRIL modulates B and T cell immunity","volume":"109","author":"Stein","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ekir.2022.01.1073_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A\u00a0proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2022.01.1073_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-381300-8.00002-2","article-title":"Innate signaling networks in mucosal IgA class switching","volume":"107","author":"Chorny","year":"2010","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ekir.2022.01.1073_bib18","author":"Begg"},{"key":"10.1016\/j.ekir.2022.01.1073_bib19","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3389\/fimmu.2018.01880","article-title":"Regulation of IgM+ B cell activities by rainbow trout APRIL reveals specific effects of this cytokine in lower vertebrates","volume":"9","author":"Soleto","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib20","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/art.23047","article-title":"Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial","volume":"56","author":"Dall\u2019Era","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2022.01.1073_bib21","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2022.01.1073_bib22","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial) [published correction appears in Ann Rheum Dis. 2016;75:946]","volume":"74","author":"Isenberg","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2022.01.1073_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fimmu.2020.00433","article-title":"Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders","volume":"11","author":"Kaegi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2022.01.1073_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/annrheumdis-2012-202071","article-title":"Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: data from a placebo-controlled clinical trial","volume":"72","author":"Pollard","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2022.01.1073_bib26","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ekir.2022.01.1073_bib27","doi-asserted-by":"crossref","first-page":"666022","DOI":"10.3389\/fimmu.2021.666022","article-title":"Modifications of the BAFF\/BAFF-receptor axis in patients with pemphigus treated with rituximab versus standard corticosteroid regimen","volume":"12","author":"H\u00e9bert","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib28","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A\u00a0randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2022.01.1073_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.1994.134","article-title":"Pharmacologic target-mediated drug disposition","volume":"56","author":"Levy","year":"1994","journal-title":"Clin Pharmacol Ther"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922011354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024922011354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:40:47Z","timestamp":1762832447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024922011354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2468024922011354"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2022.01.1073","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2022.01.1073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}